GW501516 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-07-26. Where a claim depends on a specific study, the study is described rather than over-claimed.
GW501516 acts as a ligand for PPAR delta, a nuclear receptor that regulates transcription of genes involved in fatty acid oxidation and energy use. Activation of this receptor in skeletal muscle shifts metabolism toward fat burning in animal models. The compound does not burn fat directly; it changes gene expression over hours to days. Researchers study it to understand metabolic flexibility and exercise adaptation. Effects observed in rodents are not automatically expected in humans.
Preclinical research reported that GW501516 increased running endurance in mice and improved lipid profiles in some animal species. Early human trials explored effects on high-density lipoprotein cholesterol, triglycerides, and glucose handling, but the program was discontinued. Published human data are sparse and do not establish efficacy for any condition. Studies also examined PPAR delta in cancer biology, with conflicting findings across models. The relationship between receptor activation, tissue context, and disease risk remains an active area of investigation.
Cardarine has no approved therapeutic indication and is not marketed as a medicine. The World Anti-Doping Agency lists GW501516 as a prohibited substance at all times, covering both in-competition and out-of-competition periods. National laws vary: some countries treat it as an unapproved drug subject to import controls, while others have specific restrictions on sale for human consumption. It is often sold as a research chemical, a label that does not imply safety or legality. Enforcement actions have targeted online vendors and shipments.
Anti-doping laboratories identify GW501516 and related metabolites using liquid chromatography coupled with tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be analyzed. The method targets the parent compound and phase I and phase II metabolites, which extend the detection window. Because the substance is prohibited at all times, athletes can be tested outside competition. Detection limits and windows depend on the assay, sample type, and individual metabolism.
| Property | Value | Notes |
|---|---|---|
| Molecular target | PPAR delta (NR1C2) | Ligand-activated nuclear receptor. |
| Primary tissues studied | Skeletal muscle, liver, adipose | Effects on fatty acid oxidation and energy use. |
| Typical detection matrix | Urine | Used in anti-doping analysis. |
| Common analytical method | LC-MS/MS | Detects parent compound and metabolites. |
| Sport regulatory class | Prohibited at all times | Listed as a metabolic modulator by WADA. |
Cardarine is a common name for GW501516, a synthetic compound first described in the 1990s as a selective agonist of the peroxisome proliferator-activated receptor delta. It was studied in preclinical models for metabolic and cardiovascular conditions, but it has not been approved as a medicine in the United States, Europe, or other major jurisdictions. Retail products labeled as cardarine are generally research chemicals or supplements, not pharmaceutical formulations. Because human safety and efficacy data remain limited, regulatory agencies treat it as an unapproved substance rather than a therapeutic product.
Sporting authorities added GW501516 to prohibited lists after it appeared in athlete samples and online markets. The World Anti-Doping Agency classifies it as a hormone and metabolic modulator, and its use can lead to an anti-doping rule violation. Some early laboratory work suggested effects on fatty acid oxidation and endurance-related metabolism in animals, but those findings do not establish safe or effective use in people. Reports of adverse events in humans are scarce and often anecdotal, which complicates risk assessment.
Cardarine is a common name for GW501516, also GW-1516, a synthetic compound developed as a peroxisome proliferator-activated receptor delta (PPARδ) agonist. It belongs to a class of agents that modulate gene transcription related to lipid and energy metabolism. The compound was studied in preclinical and early clinical research for metabolic and cardiovascular conditions, but it did not progress to approved therapeutic use. Its name appears in fitness and sports contexts despite not being approved as a drug.
PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.
Fossil dinosaur eggshells, like modern bird and reptile eggshells, are made up of calcium carbonate crystal units. The basic arrangement and structure of these eggshell units (called the ultrastructure) is used to divide fossil eggs into several basic types, including the spherulitic, prismatic, and ornithoid basic types, which contain dinosaurs. Dinosaur eggs further classified by the microstructural aspects of the crystalline structure of the eggshell units and by the type of their pores and their shell ornamentation.
It also reduces propranolol clearance and antagonizes the therapeutic effects of antidiabetic agents, levodopa (a Parkinson's medication. This is likely because chlorpromazine antagonizes the D2 receptor which is one of the receptors dopamine, a levodopa metabolite, activates), amphetamines and anticoagulants. It may also interact with anticholinergic drugs such as orphenadrine to produce hypoglycaemia (low blood sugar). Chlorpromazine may also interact with epinephrine (adrenaline) to produce a paradoxical fall in blood pressure. Monoamine oxidase inhibitors (MAOIs) and thiazide diuretics may also accentuate the orthostatic hypotension experienced by those receiving chlorpromazine treatment. Quinidine may interact with chlorpromazine to increase myocardial depression. Likewise, it may also antagonize the effects of clonidine and guanethidine. It also may reduce the seizure threshold and hence a corresponding titration of anticonvulsant treatments should be considered. Prochlorperazine and desferrioxamine may also interact with chlorpromazine to produce transient metabolic encephalopathy. Other drugs that prolong the QT interval, such as quinidine, verapamil, amiodarone, sotalol and methadone, may also interact with chlorpromazine to produce additive QT interval prolongation. Chlorpromazine is a serotonin 5-HT2A receptor antagonist and has been found to reduce the hallucinogenic effects of serotonergic psychedelics like LSD.
22 August A university reports the development of a driver isolation framework to protect operating system kernels, primarily the monolithic Linux kernel which gets ~80,000 commits/year to its drivers, from defects and vulnerabilities in device drivers, with the Mars Research Group developers describing this lack of isolation as one of the main factors undermining kernel security. Scientists demonstrate that tACS brain stimulation can, depending on the frequency, for one month improve (either) short-term memory or long-term memory in 65–88-years-old people. Scientists report a so far unique and unknown feature of material VO2 – it can "remember" previous external stimuli (via structural rather than electronic states), with potential for e.g. data storage. A university reports the first successful transplantation of an organoid into a human, first announced on 7 July, with the underlying study being published in February. 23 August A study reports that look-alike humans have genetic similarities, sharing genes affecting not only the face but also some phenotypes of physique and behavior, also indicating that (their) differences in the epigenome and microbiome contribute only modestly to human variability in facial appearance. Researchers introduce the concept of 'false social reality' and substantiate it by showing that (a sample of) Americans widely underestimate general public support for climate change mitigation policies by a large margin.
Sources: en.wikipedia.org
{\displaystyle \nabla \cdot {\boldsymbol {\tau }}=2\mu \nabla \cdot {\boldsymbol {\varepsilon }}=\mu \nabla \cdot \left(\nabla \mathbf {u} +\nabla \mathbf {u} ^{\mathsf {T}}\right)=\mu \,\nabla ^{2}\mathbf {u} }
=== Technical issues during the flight === On the 19th orbit, the first sign of trouble appeared when the spacecraft 0.05 g (0.5 m/s2) light came on. However, this turned out to be a faulty indicator, and the spacecraft was not reentering. On the 20th orbit, Cooper lost all attitude readings. The 21st orbit saw a short-circuit occur in the bus bar serving the 250 VA (115 V, 400 Hz) main inverter. This left the automatic stabilization and control system without electric power. On the 21st orbit, John Glenn on board the tracking ship Coastal Sentry Quebec near Kyushu, Japan, helped Cooper prepare a revised checklist for retrofire. Due to the system malfunctions, many of the steps would have to be done manually. Only Hawaii and Zanzibar were in radio range on this last orbit, but communications were good. Cooper noted that the carbon dioxide level was rising in the cabin and in his spacesuit. He told Carpenter as he passed over Zanzibar, "Things are beginning to stack up a little." Throughout the problems, Cooper remained cool, calm and collected. Cooper did not experience much of an appetite during the flight and ate only because it was scheduled. The food containers and water dispenser system proved unwieldy and he was not able to properly prepare freeze-dried food packages, so he limited his consumption to cubed food and bite-sized sandwiches. Cooper found the cubed food largely unpalatable, which contributed to his lack of eating.
=== Alzheimer's disease === Considerable interest in IDE has been stimulated due to the discovery that IDE can degrade amyloid beta (Aβ), a peptide implicated in the pathogenesis of Alzheimer's disease. The underlying cause or causes of the disease are unclear, though the primary neuropathology observed is the formation of amyloid plaques and neurofibrillary tangles. One hypothesized mechanism of disease, called the amyloid hypothesis, suggests that the causative agent is the hydrophobic peptide Aβ, which forms quaternary structures that, by an unclear mechanism, cause neuronal death. Aβ is a byproduct generated as the result of proteolytic processing of the amyloid precursor protein (APP) by proteases referred to as the β and γ secretases. The physiological role of this processing is unclear, though it may play a role in nervous system development. Numerous in vitro and in vivo studies have shown correlations between IDE, Aβ degradation, and Alzheimer's disease. Mice engineered to lack both alleles of the IDE gene exhibit a 50% decrease in Aβ degradation, resulting in cerebral accumulation of Aβ. Studies of genetically inherited forms of Alzheimer's show reduction in both IDE expression and catalytic activity among affected individuals. Despite the evident role of IDE in disease, relatively little is known about its physiological functions. These may be diverse, as IDE has been localized to several locations, including the cytosol, peroxisomes, endosomes, proteasome complexes, and the surface of cerebrovascular endothelial cells.
Sources: en.wikipedia.org
Relaxin family peptide hormones in humans are represented by seven members: three relaxin-like (RLN) and four insulin-like (INSL) peptides: RLN1, RLN2, RNL3, INSL3, INSL4, INSL5, INSL6. This subdivision into two classes (RLN and INSL) is based primarily on early findings, and does not reflect the evolutionary origins or physiological differences between peptides. For example, it is known that the genes coding for RLN3 and INSL5 arose from one ancestral gene, and INSL3 shares origin with RLN2 and its multiple duplicates: RLN1, INSL4, INSL6.
Lebrikizumab, sold under the brand name Ebglyss, is a humanized monoclonal antibody used for the treatment of atopic dermatitis (atopic eczema). It is an interleukin 13 antagonist. It is given by subcutaneous injection. The most common side effects include injection site reactions, dry eye and conjunctivitis, including allergic conjunctivitis. Lebrikizumab was approved for medical use in the European Union in November 2023, in Canada in June 2024, and in the US in September 2024.
CH stations were designed to operate at 20–50 MHz, the "boundary area" between high frequency and VHF bands at 30 MHz, although typical operations were at 20–30 MHz (the upper end of the HF band), or about a 12 m wavelength (25 MHz). The detection range was typically 120 mi (190 km; 100 nmi), but could be better. The main limitation in use was that Chain Home was a fixed system, non-rotational, which meant it could not see beyond its sixty-degree transmission arc or behind it once the targets had flown overhead, and so raid plotting over land was down to ground observers, principally the Observer Corps (from April 1941 known as the Royal Observer Corps). Ground-based observation was acceptable during the day but useless at night and in conditions of reduced visibility. This problem was lessened on introduction of more advanced surveillance radars with 360-degree tracking and height-finding capability and, more importantly, aircraft fitted with Airborne Intercept radar (AI), which had been developed in parallel with Chain Home from 1936 onwards. This new equipment began to appear in late 1940 fitted to Bristol Blenheim, Bristol Beaufighter and Boulton Paul Defiant aircraft. Even as the CH system was being deployed, a wide variety of experiments with newer designs was being carried out. By 1941 the Type 7 Ground Control Intercept Radar (GCI) on a wavelength of 1.5 m was entering production, and reached widespread service in 1942.
Sources: en.wikipedia.org
It binds to and activates PPAR delta, a nuclear receptor that controls expression of genes related to fatty acid oxidation. This mechanism can alter energy metabolism in animal models. It is not a direct stimulant or fat-burning enzyme.
Early-stage trials examined lipid and glucose markers, but the development program was discontinued. Published human results are limited and do not support approved use for any indication. Claims of performance or health benefits remain unproven.
Yes. Laboratories use LC-MS/MS to detect GW501516 and its metabolites in urine. Detection depends on timing and sensitivity, but the substance is banned at all times.
Legal status varies by country. It is not approved as a medicine, and it is prohibited in sport. Some jurisdictions restrict import, sale, or possession.